Genmab — Oktober 2017
-
Så du siger, at vi kan forvente forkert information?
-
Vi sad ellers i morges og forsøgte at regne os frem til de korrekte tal.
-
Rent faktisk var både Q1, 2 og 3 forkerte. Det var kun med præciseringen, at vi nærmede os lidt sandhed
-
Min pizzamand har en mere kompleks omsætningsside, men han har styr på det
-
-
Min pølsemand sprang også ud foran toget. Kompleksiteten i hans forretning med 2 slags spegepølse var gået ham til hovedet
-
Ofatumumab – marketed already as the chronic lymphocytic leukaemia treatment Arzerra – could emerge as a key competitor to Ocrevus, which is enjoying a strong launch in the US market. Furthermore, Novartis believes its product could benefit from a number of advantages; ofatumumab is a fully-human monoclonal antibody (Ocrevus is humanised), it can be administered via subcutaneous injection (instead of intravenously) and
-
based on cross-trial comparisons, it has demonstrated faster B-cell repletion. These factors could determine that ofatumumab is a more patient and physician-friendly treatment, argues Novartis; a view shared by KOLs recently interviewed by FirstWord for our forthcoming report. Phase III studies should complete in 2019.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind